Analysts predict that Acorda Therapeutics Inc (NASDAQ:ACOR) will announce earnings per share (EPS) of ($0.39) for the current quarter, according to Zacks. Five analysts have made estimates for Acorda Therapeutics’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.16). Acorda Therapeutics posted earnings per share of ($0.55) during the same quarter last year, which indicates a positive year-over-year growth rate of 29.1%. The company is scheduled to report its next quarterly earnings results on Thursday, August 6th.

According to Zacks, analysts expect that Acorda Therapeutics will report full-year earnings of ($1.36) per share for the current fiscal year, with EPS estimates ranging from ($1.87) to ($0.42). For the next fiscal year, analysts expect that the company will report earnings of ($1.46) per share, with EPS estimates ranging from ($2.27) to $0.15. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.05. The company had revenue of $28.10 million during the quarter, compared to the consensus estimate of $39.34 million. Acorda Therapeutics had a negative return on equity of 19.83% and a negative net margin of 131.45%.

A number of research firms have recently commented on ACOR. JPMorgan Chase & Co. restated a “sell” rating on shares of Acorda Therapeutics in a report on Sunday, February 16th. ValuEngine upgraded Acorda Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Finally, HC Wainwright restated a “neutral” rating and set a $5.00 price objective (down from $6.00) on shares of Acorda Therapeutics in a report on Wednesday, May 6th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. Acorda Therapeutics presently has an average rating of “Hold” and an average target price of $7.24.

A number of hedge funds and other institutional investors have recently made changes to their positions in ACOR. Salzhauer Michael acquired a new stake in Acorda Therapeutics in the 1st quarter valued at $28,000. Great West Life Assurance Co. Can acquired a new stake in Acorda Therapeutics in the 4th quarter valued at $92,000. UBS Group AG increased its holdings in Acorda Therapeutics by 88.1% in the 4th quarter. UBS Group AG now owns 59,617 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,918 shares in the last quarter. Everence Capital Management Inc. acquired a new stake in Acorda Therapeutics in the 4th quarter valued at $134,000. Finally, Spark Investment Management LLC acquired a new stake in Acorda Therapeutics in the 4th quarter valued at $225,000. Hedge funds and other institutional investors own 89.09% of the company’s stock.

ACOR traded down $0.02 during trading on Wednesday, hitting $0.75. The company’s stock had a trading volume of 1,684,900 shares, compared to its average volume of 2,075,470. The firm’s 50 day moving average price is $0.92 and its 200-day moving average price is $1.51. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.38 and a quick ratio of 2.02. The stock has a market cap of $36.52 million, a PE ratio of -0.15 and a beta of 1.53. Acorda Therapeutics has a twelve month low of $0.70 and a twelve month high of $9.66.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Read More: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.